Condition: Colorectal Cancer Metastatic · Colorectal Cancer Recurrent · Colorectal Cancer Stage IV · Sponsor: Shanghai Changzheng Hospital
This study is a single-arm, open-label, exploratory clinical trial. Building on the previous dose-escalation trial, this dose-expansion trial aims to evaluate the safety and tolerability of intravenous monotherapy with CD-GA-102 or its combination with immunotherapy and other systemic treatments in patients with unresectable locally advanced or metastatic colorectal cancer, and to preliminarily explore its efficacy in treating colorectal cancer.
This description comes directly from the study's public registry record.
Wen-Ping Xu, MD. PhD · +862115026590980 · xwp198527@sina.com
Weifen Xie, MD. PhD · +862113701682806 · weifenxie@medmail.com.cn
Always discuss trial participation with your own doctor first.
| Shanghai Changzheng Hospital | Shanghai, None Selected, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07050394